• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

纳武单抗诱发晚期转移性黑色素瘤患者新发血清阴性类风湿关节炎：一例报告及文献综述

Nivolumab-induced new-onset seronegative rheumatoid arthritis in a patient with advanced metastatic melanoma: A case report and literature review.

作者信息

Haikal Ammar, Borba E, Khaja Taqui, Doolittle Gary, Schmidt Paul

机构信息

Department of Internal Medicine, University of Kansas Medical Center, Kansas, USA.

Department of Orthopedic Surgery, Cajuru Hospital, Curitiba, Brazil.

出版信息

Avicenna J Med. 2018 Jan-Mar;8(1):34-36. doi: 10.4103/ajm.AJM_127_17.

DOI:10.4103/ajm.AJM_127_17
PMID:29404271
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5782418/
Abstract

Immune-related adverse events have been reported in patients treated with anti-programmed death-1 receptor drugs such as nivolumab. We present a case of a new-onset seronegative rheumatoid arthritis in a patient with metastatic melanoma treated with nivolumab.

摘要

在接受纳武单抗等抗程序性死亡-1受体药物治疗的患者中，已报告了免疫相关不良事件。我们报告一例接受纳武单抗治疗的转移性黑色素瘤患者新发血清阴性类风湿关节炎的病例。

相似文献

1
Nivolumab-induced new-onset seronegative rheumatoid arthritis in a patient with advanced metastatic melanoma: A case report and literature review.纳武单抗诱发晚期转移性黑色素瘤患者新发血清阴性类风湿关节炎：一例报告及文献综述
Avicenna J Med. 2018 Jan-Mar;8(1):34-36. doi: 10.4103/ajm.AJM_127_17.
2
A case report of using nivolumab for a malignant melanoma patient with rheumatoid arthritis.使用纳武单抗治疗一名患有类风湿性关节炎的恶性黑色素瘤患者的病例报告。
Int Cancer Conf J. 2016 Jul 23;5(4):192-196. doi: 10.1007/s13691-016-0256-8. eCollection 2016 Oct.
3
Nivolumab-induced vitiligo in a metastatic melanoma patient: A case report.纳武单抗诱发转移性黑色素瘤患者白癜风：一例报告
J Oncol Pharm Pract. 2017 Dec;23(8):629-634. doi: 10.1177/1078155216667636. Epub 2016 Sep 8.
4
Combination Nivolumab/Ipilimumab Immunotherapy For Melanoma With Subsequent Unexpected Cardiac Arrest: A Case Report and Review of Literature.纳武利尤单抗/伊匹单抗免疫治疗黑色素瘤后继发意外心脏骤停：病例报告及文献复习。
J Immunother. 2019 Oct;42(8):313-317. doi: 10.1097/CJI.0000000000000282.
5
Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.免疫检查点抑制剂相关的类肉瘤样肉芽肿性炎症：在接受晚期恶性黑色素瘤治疗的患者的淋巴结细针抽吸细胞学中检测到的一种罕见不良事件。
Hum Pathol. 2019 Sep;91:69-76. doi: 10.1016/j.humpath.2019.07.001. Epub 2019 Jul 4.
6
Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma.转移性黑色素瘤序贯伊匹单抗-纳武单抗治疗后发生急性间质性肾炎。
J Immunother Cancer. 2017 Jul 18;5(1):57. doi: 10.1186/s40425-017-0261-2.
7
Early Onset Immune-Related Adverse Event to Identify Pseudo-Progression in a Patient With Ovarian Cancer Treated With Nivolumab: A Case Report and Review of the Literature.早期发生的免疫相关不良事件用于识别接受纳武单抗治疗的卵巢癌患者的假性进展：一例病例报告及文献综述
Front Med (Lausanne). 2020 Jul 28;7:366. doi: 10.3389/fmed.2020.00366. eCollection 2020.
8
Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature.纳武单抗治疗转移性非小细胞肺癌期间银屑病关节炎的发生、临床结局分析及文献综述
Lung Cancer. 2017 Jun;108:217-221. doi: 10.1016/j.lungcan.2017.04.007. Epub 2017 Apr 14.
9
Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma.纳武单抗致转移性黑色素瘤患者发生致死性再生障碍性贫血
Case Rep Oncol. 2019 Jan 4;12(1):29-32. doi: 10.1159/000495980. eCollection 2019 Jan-Apr.
10
Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab.尼伏单抗诱导的缓解性血清阴性对称性滑膜炎伴凹陷性水肿（RS3PE）综合征。
Semin Arthritis Rheum. 2017 Oct;47(2):281-287. doi: 10.1016/j.semarthrit.2017.03.003. Epub 2017 Mar 8.

引用本文的文献

1
Biomarkers in Cancer Detection, Diagnosis, and Prognosis.癌症检测、诊断和预后中的生物标志物。
Sensors (Basel). 2023 Dec 20;24(1):37. doi: 10.3390/s24010037.
2
Seronegative Rheumatoid Arthritis Secondary to Immune Checkpoint Inhibitor in a Renal Cell Carcinoma Patient Encountered in a Rural Community-Based Rheumatology Clinic: A Case Report.农村社区风湿病诊所收治的一名肾细胞癌患者继发于免疫检查点抑制剂的血清阴性类风湿关节炎：一例报告
Cureus. 2023 Jul 5;15(7):e41394. doi: 10.7759/cureus.41394. eCollection 2023 Jul.
3
Seronegative rheumatoid arthritis after combination therapy with ipilimumab and nivolumab for postoperative pancreatic and liver metastases from renal cell carcinoma.肾细胞癌术后胰腺和肝转移接受伊匹木单抗和纳武单抗联合治疗后出现血清阴性类风湿性关节炎
IJU Case Rep. 2022 Nov 30;6(2):101-105. doi: 10.1002/iju5.12560. eCollection 2023 Mar.
4
Editorial Comment on Seronegative rheumatoid arthritis after combination therapy with Ipilimumab and Nivolumab for postoperative pancreatic and liver metastases from renal cell carcinoma.关于伊匹木单抗和纳武单抗联合治疗肾细胞癌术后胰腺和肝转移后血清阴性类风湿性关节炎的社论评论。
IJU Case Rep. 2023 Jan 4;6(2):105-106. doi: 10.1002/iju5.12574. eCollection 2023 Mar.
5
Immune checkpoint inhibitor-associated arthritis in advanced pulmonary adenocarcinoma: A case report.晚期肺腺癌中免疫检查点抑制剂相关关节炎：一例报告
World J Clin Cases. 2022 Oct 16;10(29):10701-10707. doi: 10.12998/wjcc.v10.i29.10701.
6
Inflammatory markers in autoimmunity induced by checkpoint inhibitors.免疫检查点抑制剂诱导的自身免疫中的炎症标志物。
J Cancer Res Clin Oncol. 2021 Jun;147(6):1623-1630. doi: 10.1007/s00432-021-03550-5. Epub 2021 Apr 10.
7
Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors.免疫检查点抑制剂相关风湿性不良事件的诊断与治疗。
J Immunol Res. 2020 Aug 4;2020:2640273. doi: 10.1155/2020/2640273. eCollection 2020.
8
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.EULAR 针对癌症免疫治疗中使用检查点抑制剂引起的风湿免疫相关不良事件的诊断和管理的考虑要点。
Ann Rheum Dis. 2021 Jan;80(1):36-48. doi: 10.1136/annrheumdis-2020-217139. Epub 2020 Apr 23.
9
Management of immune checkpoint inhibitor-related adverse events: A review of case reports.免疫检查点抑制剂相关不良反应的管理：病例报告综述。
Thorac Cancer. 2020 Mar;11(3):498-504. doi: 10.1111/1759-7714.13315. Epub 2020 Jan 22.
10
Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy.与检查点抑制剂治疗相关的风湿综合征的临床特征。
Rheumatology (Oxford). 2019 Dec 1;58(Suppl 7):vii68-vii74. doi: 10.1093/rheumatology/kez295.

本文引用的文献

1
Nivolumab-Induced Recurrence of Rheumatoid Arthritis in a Patient With Advanced Non-Small Cell Lung Cancer: A Case Report.
Ann Intern Med. 2016 Dec 20;165(12):894-895. doi: 10.7326/L16-0137.
2
Fulminant Myocarditis with Combination Immune Checkpoint Blockade.暴发性心肌炎合并免疫检查点阻断治疗
N Engl J Med. 2016 Nov 3;375(18):1749-1755. doi: 10.1056/NEJMoa1609214.
3
The Checkpoint Immunotherapy Revolution: What Started as a Trickle Has Become a Flood, Despite Some Daunting Adverse Effects; New Drugs, Indications, and Combinations Continue to Emerge.检查点免疫疗法革命：尽管存在一些令人畏惧的不良反应，但起初如涓涓细流的它已发展成洪流；新药、适应症及联合疗法不断涌现。
P T. 2016 Mar;41(3):185-91.
4
Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy.抗 PD-1 抗体治疗相关免疫相关不良药物反应的诊断、监测和管理。
Cancer Treat Rev. 2016 Apr;45:7-18. doi: 10.1016/j.ctrv.2016.02.003. Epub 2016 Feb 18.
5
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.癌症治疗中的PD-1/PD-L1阻断：观点与问题
Int J Clin Oncol. 2016 Jun;21(3):462-73. doi: 10.1007/s10147-016-0959-z. Epub 2016 Feb 22.
6
PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses.PD-1通路抑制剂：用于恢复抗肿瘤免疫反应的免疫肿瘤学药物。
Pharmacotherapy. 2016 Mar;36(3):317-34. doi: 10.1002/phar.1714.
7
Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma.抗PD-1治疗转移性黑色素瘤所致的自身免疫性溶血性贫血
Melanoma Res. 2016 Apr;26(2):202-4. doi: 10.1097/CMR.0000000000000232.
8
Nivolumab for treating non-small cell lung cancer.纳武单抗用于治疗非小细胞肺癌。
Expert Opin Biol Ther. 2015;15(12):1789-97. doi: 10.1517/14712598.2015.1114097. Epub 2015 Nov 16.
9
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.2015年美国风湿病学会类风湿关节炎治疗指南
Arthritis Care Res (Hoboken). 2016 Jan;68(1):1-25. doi: 10.1002/acr.22783. Epub 2015 Nov 6.
10
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.试验观察：用于肿瘤适应症的免疫调节单克隆抗体
Oncoimmunology. 2015 Mar 2;4(4):e1008814. doi: 10.1080/2162402X.2015.1008814. eCollection 2015 Apr.